Documents | Ranibizumab for treating diabetic macular oedema | Guidance | NICE

Documents

A list of downloadable documents created during development.

Background information

TA274 Macular oedema (diabetic) - ranibizumab: review decision - April 2015 information
TA274 Macular oedema (diabetic) - ranibizumab: appendix A - GE decision paper - March 2015 ^{PDF 67.61 KB} 10 April 2015
TA274 Macular oedema (diabetic) - ranibizumab: review proposal - February 2015 information
TA274 Macular oedema (diabetic) - ranibizumab: appendix A - GE proposal paper February 2015 ^{PDF 499.6 KB} 23 February 2015
TA274 Macular oedema (diabetic) - ranibizumab: appendix A - matrix of stakeholders ^{PDF 40.72 KB} 23 February 2015
TA274 Macular oedema (diabetic) - ranibizumab: press release information
NICE Single Technology Appraisal process guide ^{PDF 285.78 KB} 06 December 2013

Macular oedema (diabetic) - ranibizumab (rapid review of TA237): equality impact assessment - guidance development

Macular oedema (diabetic) - ranibizumab (rapid review of TA237): equality impact assessment - guidance development ^{PDF 18.24 KB} 02 July 2013

Macular oedema (diabetic) - ranibizumab (rapid review of TA237): final appraisal determination

Macular oedema (diabetic) - ranibizumab (rapid review of TA237): final appraisal determination information
Macular oedema (diabetic) - ranibizumab (rapid review of TA237): final appraisal determination guidance ^{PDF 277.51 KB} 04 January 2013
Macular oedema (diabetic) - ranibizumab (rapid review of TA237): response to consultee, commentator and public comments on the Appraisal Consultation Document (ACD) ^{PDF 138.28 KB} 04 January 2013
Macular oedema (diabetic) - ranibizumab (rapid review of TA237): consultee and commentator comments on the ACD
Macular oedema (diabetic) - ranibizumab (rapid review of TA237): Novartis ^{PDF 189.3 KB} 04 January 2013
Macular oedema (diabetic) - ranibizumab (rapid review of TA237): Diabetes UK ^{PDF 66.94 KB} 04 January 2013
Macular oedema (diabetic) - ranibizumab (rapid review of TA237): RNIB ^{PDF 27.98 KB} 04 January 2013
Macular oedema (diabetic) - ranibizumab (rapid review of TA237): RCP and ABCD ^{PDF 13.76 KB} 04 January 2013
Macular oedema (diabetic) - ranibizumab (rapid review of TA237): CSAS ^{PDF 107.58 KB} 04 January 2013
Macular oedema (diabetic) - ranibizumab (rapid review of TA237): Department of Health ^{PDF 8.33 KB} 04 January 2013
Macular oedema (diabetic) - ranibizumab (rapid review of TA237): comments on the ACD received from the public through the NICE website ^{PDF 83.23 KB} 04 January 2013

Macular oedema (diabetic) - ranibizumab (rapid review of TA237): appraisal consultation

Macular oedema (diabetic) - ranibizumab (rapid review of TA237): appraisal consultation
Macular oedema (diabetic) - ranibizumab (rapid review of TA237): appraisal consultation document information
Macular oedema (diabetic) - ranibizumab (rapid review of TA237): evaluation report
Macular oedema (diabetic) - ranibizumab (rapid review of TA237): pre-meeting briefing ^{PDF 86.01 KB} 05 October 2012
Macular oedema (diabetic) - ranibizumab (rapid review of TA237): Evidence Review Group report for NICE rapid review ^{PDF 319.01 KB} 05 October 2012
Macular oedema (diabetic) - ranibizumab (rapid review of TA237): Novartis ^{PDF 299.13 KB} 05 October 2012

Macular oedema (diabetic) - ranibizumab (rapid review of TA237): final scope

Macular oedema (diabetic) - ranibizumab (rapid review of TA237): final scope ^{PDF 28.15 KB} 05 October 2012